D. Boral Capital Reiterates Buy Rating for Pulmonx (NASDAQ:LUNG)

Pulmonx (NASDAQ:LUNG)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $14.00 target price on the stock.

A number of other analysts also recently issued reports on the stock. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $5.38.

Pulmonx Stock Up 25.5%

Shares of NASDAQ:LUNG opened at $2.02 on Thursday. The company has a market capitalization of $83.33 million, a PE ratio of -1.52 and a beta of 0.07. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15. The business has a fifty day moving average price of $1.75 and a two-hundred day moving average price of $1.79. Pulmonx has a 1 year low of $1.31 and a 1 year high of $8.12.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.14. The firm had revenue of $22.60 million during the quarter, compared to analyst estimates of $21.73 million. Pulmonx had a negative return on equity of 78.35% and a negative net margin of 59.67%. Analysts forecast that Pulmonx will post -1.55 earnings per share for the current year.

Insider Activity

In other news, CEO Glendon E. French III sold 67,813 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $1.43, for a total transaction of $96,972.59. Following the transaction, the chief executive officer owned 1,409,511 shares of the company’s stock, valued at $2,015,600.73. This represents a 4.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 98,265 shares of company stock valued at $140,519 in the last 90 days. Insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Pulmonx

Several large investors have recently added to or reduced their stakes in the company. Corton Capital Inc. bought a new stake in Pulmonx in the 2nd quarter valued at about $32,000. Cerity Partners LLC bought a new position in Pulmonx during the fourth quarter worth about $27,000. Opal Capital LLC bought a new position in Pulmonx during the fourth quarter worth about $29,000. Regatta Capital Group LLC purchased a new position in shares of Pulmonx in the fourth quarter worth about $30,000. Finally, Lazard Asset Management LLC purchased a new position in shares of Pulmonx in the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Key Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx beat Q4 expectations — EPS -$0.25 vs. consensus ~- $0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year‑over‑year, signaling operational progress. Read More.
• Positive Sentiment: Closed a five‑year senior secured credit facility with Perceptive Advisors (initial $40M draw; up to $60M total subject to milestones), which refinanced prior debt and extends maturities to 2031 — materially improves near‑term liquidity. Read More.
• Positive Sentiment: Gross margin and cost discipline improved — Q4 gross margin ~78% and operating expenses down ~11% vs. prior year quarter, supporting a clearer path toward profitability if revenue momentum returns. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating (high target), which can attract momentum buyers given large upside vs. current levels. Read More.
• Neutral Sentiment: Management outlined a strategic restructuring and sales‑force changes on the earnings call — intended to re‑accelerate commercial growth but the near‑term impact on procedure volumes is unclear. Read More.
• Neutral Sentiment: Some analysts updated targets (Canaccord trimmed its target but kept a Buy rating) — mixed analyst activity keeps coverage but shows differing views on recovery timing. Read More.
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below consensus (~$94M), implying slower top‑line growth and limiting near‑term upside despite margin improvements. Read More.
• Negative Sentiment: Insider selling was reported (CEO, general counsel and other officers sold shares on March 2), which can increase perceived selling pressure and weigh on sentiment. Read More.
• Negative Sentiment: The new loan carries a high effective cost (SOFR + 7.0% with 3.75% floor and a 2% PIK option) and includes warrants — helpful for liquidity but increases interest burden and potential dilution if exercised. Read More.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.